LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 107 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,977 | -16.3% | 15,235 | 0.0% | 0.00% | – |
| Q2 2023 | $21,481 | +26.4% | 15,235 | +2.0% | 0.00% | – |
| Q3 2022 | $17,000 | -73.8% | 14,937 | -63.6% | 0.00% | – |
| Q2 2022 | $65,000 | -7.1% | 41,065 | -9.1% | 0.00% | – |
| Q1 2022 | $70,000 | -63.7% | 45,159 | -42.6% | 0.00% | – |
| Q4 2021 | $193,000 | -38.3% | 78,742 | -36.6% | 0.00% | – |
| Q3 2021 | $313,000 | -14.7% | 124,219 | -3.5% | 0.00% | – |
| Q2 2021 | $367,000 | +4487.5% | 128,767 | +1185.7% | 0.00% | – |
| Q1 2020 | $8,000 | -27.3% | 10,015 | -12.4% | 0.00% | – |
| Q3 2019 | $11,000 | – | 11,427 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,005,379 | $85,694,000 | 4.37% |
| Defender Capital, LLC. | 4,798,270 | $12,707,000 | 4.13% |
| Raffles Associates | 93,590 | $236,000 | 0.22% |
| Prescott General Partners LLC | 1,851,851 | $4,667,000 | 0.16% |
| DCF Advisers, LLC | 87,000 | $219,000 | 0.10% |
| Laidlaw Wealth Management LLC | 104,841 | $264,000 | 0.07% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $113,000 | 0.06% |
| Strategic Wealth Investment Group, LLC | 70,625 | $179,000 | 0.05% |
| Fort Sheridan Advisors LLC | 47,931 | $121,000 | 0.04% |
| Sightline Wealth Advisors, LLC | 14,958 | $38,000 | 0.03% |